BioStock: Ultimovacs protects cancer vaccine technology until 2037
Norwegian biotech Ultimovacs has announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office regarding its universal cancer vaccine UV1 in combination with various classes of checkpoint inhibitors. Once formally granted, the patent will protect Ultimovacs’ technology until at least June 2037.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/